Core Viewpoint - A securities class action lawsuit has been filed against XPLR Infrastructure, LP, alleging misleading statements and omissions regarding the company's financial condition and business model during the class period from September 27, 2023, to January 27, 2025 [1][3]. Company Overview - XPLR Infrastructure, LP, formerly known as Nextera Energy Partners, LP, focuses on acquiring, owning, and managing contracted clean energy projects in the United States, including wind and solar power projects and a natural gas pipeline [2]. Allegations in the Class Action - The lawsuit claims that during the class period, the defendants made misleading statements about XPLR's operations as a yieldco, which is a business model focused on delivering cash distributions to investors [3]. - Specific allegations include: - XPLR was struggling to maintain its yieldco operations [3]. - Defendants entered financing arrangements to temporarily alleviate operational issues while downplaying associated risks [3]. - The company could not resolve these financings before maturity without risking significant unitholder dilution [3]. - Defendants planned to halt cash distributions to redirect funds to resolve financing issues [3]. - The yieldco business model and distribution growth rate were deemed unsustainable [3]. - Public statements made by the defendants were materially false and misleading [3]. Market Reaction - On January 28, 2025, XPLR announced it would suspend cash distributions to common unitholders and abandon its yieldco model, leading to a significant drop in the stock price from $15.80 to $10.49 per unit, a decline of nearly 35% [4].

ATLANTA, July 11, 2025 (GLOBE NEWSWIRE) -- Holzer & Holzer, LLC is investigating whether Capricor Therapeutics, Inc. ("Capricor" or the "Company") (NASDAQ: CAPR) complied with federal securities laws. On July 11, 2025, Capricor announced that it had received a Complete Response Letter ("CRL") from the FDA regarding its Biologics License Application ("BLA") for Deramiocel. Following this news, the price of the Company's stock dropped. CONTACT: Corey Holzer, Esq. (888) 508-6832 (toll-free) cholzer@holzerlaw.c ...

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses in iRobot To Contact Him Directly To Discuss Their Options If you purchased or acquired securities in iRobot between January 29, 2024 and March 11, 2025 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310). [You may also click here for additional information] NEW YORK, July 11, 2025 (GLOBE NEWSWIRE) -- Faruqi & ...

NEW YORK, July 08, 2025 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP notifies investors in Bitfarms Ltd. ("Bitfarms Ltd." or the "Company") (NASDAQ: BITF) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Bitfarms Ltd. investors who were adversely affected by alleged securities fraud between March 21, 2023 and December 9, 2024. Follow the link below to get more information and be contacted by a member of our team: https://zlk.com/pslra-1/bitfarms-ltd-lawsu ...

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $50,000 In Rocket Pharmaceuticals To Contact Him Directly To Discuss Their OptionsIf you suffered losses exceeding $50,000 in Rocket Pharmaceuticals between February 27, 2025 and May 26, 2025 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310).[You may also click here for additional information]NEW YOR ...

Core Viewpoint - Faruqi & Faruqi, LLP is investigating potential claims against Rocket Pharmaceuticals due to misleading statements regarding the safety of its clinical trial for RP-A501, which led to significant investor losses [3][5][6]. Group 1: Legal Investigation and Claims - Faruqi & Faruqi is encouraging investors who suffered losses exceeding $50,000 in Rocket Pharmaceuticals between February 27, 2025, and May 26, 2025, to discuss their legal options [1]. - The firm reminds investors of the August 11, 2025, deadline to seek the role of lead plaintiff in a federal securities class action against Rocket Pharmaceuticals [3]. - The complaint alleges that Rocket Pharmaceuticals provided positive statements while concealing material adverse facts about the safety of RP-A501 and the clinical trial protocol [5]. Group 2: Clinical Trial Issues - Rocket Pharmaceuticals faced a clinical hold from the FDA on the RP-A501 Phase 2 pivotal study after a patient suffered a Serious Adverse Event (SAE), which ultimately resulted in death [6]. - The company amended the trial protocol to introduce a new immunomodulatory agent without disclosing this critical update to investors, which is a key point of contention in the lawsuit [5][6]. Group 3: Stock Price Impact - Following the announcement of the clinical hold, Rocket's stock price plummeted from $6.27 per share on May 23, 2025, to $2.33 per share on May 27, 2025, marking a decline of approximately 37% in just one trading day [8].

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $100,000 Petco To Contact Him Directly To Discuss Their Options If you suffered losses exceeding $100,000 in Petco between January 14, 2021 and June 5, 2025 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310). [You may also click here for additional information] NEW YORK, July 06, 2025 (GLOBE NEWSWIRE ...

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $50,000 In PepGen To Contact Him Directly To Discuss Their Options If you suffered losses exceeding $50,000 in PepGen between March 7, 2024 and March 3, 2025 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310). [You may also click here for additional information] NEW YORK, July 06, 2025 (GLOBE NEWSWIR ...

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Vestis To Contact Him Directly To Discuss Their OptionsIf you purchased or acquired securities in Vestis between May 2, 2024 and May 6, 2025 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310).[You may also click here for additional information]NEW YORK, July 3, 2025 /PRNewswire/ -- Faruqi & Faruqi, LLP, a le ...

Core Viewpoint - Faruqi & Faruqi, LLP is investigating potential claims against Sarepta Therapeutics, Inc. due to allegations of violations of federal securities laws related to misleading statements about the safety of its product ELEVIDYS [2][4]. Group 1: Legal Investigation and Claims - The law firm is encouraging investors who suffered losses in Sarepta between June 22, 2023, and June 24, 2025, to discuss their legal rights [1]. - There is a deadline of August 25, 2025, for investors to seek the role of lead plaintiff in a federal securities class action against Sarepta [2]. - The complaint alleges that Sarepta and its executives made false statements regarding the safety of ELEVIDYS, which posed significant risks to patients [4]. Group 2: Stock Price Impact - Following a safety update on March 18, 2025, where a patient died after treatment with ELEVIDYS, Sarepta's stock price fell by $27.81, or 27.44%, closing at $73.54 [5]. - On April 4, 2025, after the company disclosed that EU authorities requested a review of the death, the stock price dropped by $4.18, or 7.13%, closing at $54.43 [6]. - A second patient death was reported on June 15, 2025, leading to a significant stock price decline of $15.24, or 42.12%, closing at $20.91 [7][8]. - Following an FDA Safety Communication on June 24, 2025, regarding the investigation of acute liver failure risks, the stock price fell by $1.52, or 8.01%, closing at $17.46 [8][9]. Group 3: Company Background - Faruqi & Faruqi, LLP is a national securities law firm with a history of recovering hundreds of millions of dollars for investors since its founding in 1995 [3].